secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117760
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Q3 prescription revenue $3.1M (+412% YoY); net loss widens to $12.5M
--------------------------------------------------------------------------------

- Prescription product net revenue $3.1M in Q3 2022, up 8.2% QoQ and 412% YoY vs $0.6M.
- Net loss $12.5M ($0.12/sh) vs $12.2M loss in Q3 2021; operating loss $9.9M vs $9.5M.
- R&D expense rose to $5.9M from $3.3M driven by Phase 3 crofelemer CTD trial.
- OnTarget Phase 3 CTD trial targets enrollment completion in Q2 2023.
- Non-GAAP EBITDA loss $8.5M, flat YoY; no guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/0001104659-22-117760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465922117760/tm2230421d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer